Our in-house research team - ZKB Equity Research - regularly provides valuable assessments of expected developments on the markets. If the research team rates a stock as "overweight", this means that it expects outperformance. Investors who want to participate in these developments and at the same time appreciate the features of products with barriers can benefit from attractive yield enhancement products.
All shares of the following (Callable) Barrier Reverse Convertible are rated "overweight" by ZKB Equity Research.
Barrier Reverse Convertible on Nestlé, Zurich, Novartis, Roche and Swisscom (CHF)
Barrier Reverse Convertible on Clariant, Givaudan, Holcim and Sika (CHF)
Callable BRC on Nestlé, Novartis, Roche, Zurich and Givaudan (CHF)
A good way to profit from markets that continue to recover rapidly is to invest in the respective leading indices. These can be seen as a proxy for the respective economies - if these are on a good course, share prices usually follow upwards as well.
Callable BRC on SMI®, Euro Stoxx 50® and S&P500®
*indicative
ZKB Discount-Zertifikat Nestlé SA Namenaktie 121826861 / CH1218268618 |
ZKB Barrier Reverse Convertible on worst of BASF SE/LANXESS AG/Symrise AG 142532242 / CH1425322422 |
ZKB Barrier Reverse Convertible on worst of Walmart Inc/Costco Wholesale Corp/Target Corp 140250696 / CH1402506963 |
ZKB Barrier Reverse Convertible on worst of BASF SE/LANXESS AG 144653376 / CH1446533767 |
0.88% (0.50% p.a.) ZKB Barrier Reverse Convertible Last Look on worst of mit Partizipation Cap Gemin... 149281038 / CH1492810382 |